Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reply to Hojný et al.: Fusion-driven vs. fusion-negative high-grade endometrial stromal sarcoma.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Cellular responses to FGF1 are modulated by palmitoylation of the docking protein FRS2α.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Integrated mutational landscape analysis of endometrial stromal sarcoma.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Cellular responses to FGF1 are modulated by palmitoylation of the docking protein FRS2α.

bioRxiv : the preprint server for biology·2025

Same author

Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer.

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

Inducible FAK loss but not FAK inhibition in endothelial cells of PYK2-null mice activates p53 tumor suppressor to prevent tumor growth.

Molecular biology of the cell·2025

Same journal

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026

Same journal

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026

Same journal

Co-medications and gut microbiome in NSCLC immunotherapy.

The Lancet. Oncology·2026

Same journal

Carcinogenicity of butyl benzyl phthalate, dibutyl phthalate, and diisononyl phthalate.

The Lancet. Oncology·2026

Same journal

New report sheds light on cancer disparities in the USA.

The Lancet. Oncology·2026

Same journal

Review highlights gaps in South Africa's cancer care.

The Lancet. Oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 16, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing ¹⁸F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

A step towards treating KRAS-mutant NSCLC

Sarah B Goldberg¹, Joseph Schlessinger, Julie L Boyer

¹Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA.

The Lancet. Oncology

|December 4, 2012

Summary

No abstract available in PubMed .

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Experiment Videos

Last Updated: May 16, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing ¹⁸F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023